← back to search

Julia Benzel

German Cancer Research Center · DE
Area of research
Genetics · Pulmonary and Respiratory Medicine
Research interest
Research interests include Glioma Diagnosis and Treatment, Ferroptosis and cancer prognosis, Radiomics and Machine Learning in Medical Imaging, and Mass Spectrometry Techniques and Applications.
h-index
13
citations
790
works
53
NIH funding
primary concept
email

Recent publications

Experimental Insights and Recommendations for Successfully Performing Cerebral Microdialysis With Hydrophobic Drug Candidates
Clinical and Translational Science 2025cited by 2position: middledoi
EPEN-20. LEVERAGING ABERRANT EXTRACELLULAR VESICLE SIGNALING FOR TARGETED DRUG REPURPOSING IN PEDIATRIC EPENDYMOMA
Neuro-Oncology 2024cited by 1position: middledoi
Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies
Clinical Pharmacology & Therapeutics 2023cited by 9position: middledoi
The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models
Neuro-Oncology 2022cited by 49position: middledoi
Analytical Performance Evaluation of New DESI Enhancements for Targeted Drug Quantification in Tissue Sections
Pharmaceuticals 2022cited by 15position: middledoi
EPEN-28. Oncogenic dependency of pediatric ependymomas on extracellular vesicle pathways
Neuro-Oncology 2022cited by 2position: middledoi
Important Requirements for the Selection of Internal Standards during the Development of Desorption/Ionization Assays for Drug Quantification in Biological Matrices—A Practical Example
Molecules 2022cited by 2position: middledoi
Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas
Cancer Discovery 2021cited by 109position: middledoi
Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors
Acta Neuropathologica 2021cited by 77position: middledoi
Targeting Aggressive Pituitary Adenomas at the Molecular Level—A Review
Journal of Clinical Medicine 2021cited by 16position: middledoi
Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives
Molecules 2021cited by 15position: middledoi
Investigating the Central Nervous System Disposition of Actinomycin D: Implementation and Evaluation of Cerebral Microdialysis and Brain Tissue Measurements Supported by UPLC-MS/MS Quantification
Pharmaceutics 2021cited by 7position: firstdoi
Bioanalysis of selinexor in mouse plasma micro-samples utilizing UPLC-MS/MS
Journal of Chromatography B 2021cited by 6position: middledoi
Recurrent fusions in <i>PLAGL1</i> define a distinct subset of pediatric-type supratentorial ependymoma
bioRxiv (Cold Spring Harbor Laboratory) 2021cited by 0position: middledoi
Rapid and Sensitive Drug Quantification in Tissue Sections Using Matrix Assisted Laser Desorption Ionization-Ion Mobility-Mass Spectrometry Profiling
Journal of the American Society for Mass Spectrometry 2020cited by 15position: middledoi
Selective estrogen receptor modulators decrease invasiveness in pituitary adenoma cell lines AtT‐20 and TtT/GF by affecting expression of MMP‐14 and ADAM12
FEBS Open Bio 2020cited by 12position: middledoi
EPEN-44. EXTRACELLULAR VESICLES OF SUPRATENTORIAL EPENDYMOMA RELA MEDIATE INTERACTIONS WITH CELLS OF THE TUMOR MICROENVIRONMENT
Neuro-Oncology 2020cited by 1position: middledoi
Abstract B71: Molecular heterogeneity and novel oncogenic fusions in <i>RELA-</i> and <i>YAP1-</i>negative supratentorial ependymoma
Cancer Research 2020cited by 0position: middledoi
Abstract A25: Evaluation of Drug Disposition in Supratentorial Ependymoma
Cancer Research 2020cited by 0position: firstdoi
MYCN amplification drives an aggressive form of spinal ependymoma
Acta Neuropathologica 2019cited by 177position: middledoi
Degradome of soluble ADAM10 and ADAM17 metalloproteases
Cellular and Molecular Life Sciences 2019cited by 65position: middledoi
Familial Pancreatic Cancer
Oncology Research and Treatment 2018cited by 50position: firstdoi
Chemoprevention and Treatment of Pancreatic Cancer: Update and Review of the Literature
Digestion 2018cited by 20position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Stefan M. Pfister · Université du Québec12 papers (2020–2025)Kristian W. Pajtler · German Cancer Research Center12 papers (2020–2025)Jürgen Burhenne · Columbus Oncology and Hematology Associates8 papers (2020–2025)Walter E. Haefeli · Chirurgische Universitätsklinik Heidelberg7 papers (2020–2022)Kendra K. Maaß · German Cancer Research Center6 papers (2020–2025)Rémi Longuespée · Institut National des Sciences Appliquées de Strasbourg5 papers (2020–2025)Margaux Fresnais · Heidelberg University4 papers (2020–2022)Max Sauter · Heidelberg University4 papers (2020–2025)Jörg W. Bartsch · Philipps University of Marburg3 papers (2019–2021)Britta Statz · German Cancer Research Center3 papers (2020–2022)Torsten Mueller · German Cancer Research Center3 papers (2020–2024)Tatjana Wedig · German Cancer Research Center3 papers (2020–2024)Julia Sundheimer · German Cancer Research Center3 papers (2022–2025)Mieke Roosen · Princess Máxima Center3 papers (2020–2024)Jeroen Krijgsveld · Medical Research Council3 papers (2020–2024)Till Milde · Children's Cancer Center2 papers (2020–2023)Abigail Davis · Queen's University2 papers (2020–2021)Daniel Senfter · Vienna General Hospital2 papers (2022–2024)Marcel Kool · European Bioinformatics Institute2 papers (2020–2020) · 2 papers (2020–2021)